Jubilant Pharmova Limited Stock Price Today (NSE: JUBLPHARMA)
Fundamental Score
Jubilant Pharmova Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Jubilant Pharmova Limited share price today is ₹1002.50, down 0.93% on NSE/BSE as of 16 September 2026. Jubilant Pharmova Limited (JUBLPHARMA) is a Mid-cap company in the Pharmaceuticals sector with a market capitalisation of ₹15.84K (Cr). The 52-week high for JUBLPHARMA share price is ₹1184.80 and the 52-week low is ₹786.05. At a P/E ratio of 45.10x, JUBLPHARMA is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 5.97% and a debt-to-equity ratio of 0.45.
Jubilant Pharmova Limited Share Price Chart — NSE/BSE Historical Performance
Jubilant Pharmova Limited share price chart: 3.64% return over the past month. 52-week high ₹1184.80, 52-week low ₹786.05.
Jubilant Pharmova Limited — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹1010.00 | ₹1010.00 | ₹977.50 | ₹1002.50 | 1.54L (Cr) | |
| ₹1040.00 | ₹1041.00 | ₹1002.15 | ₹1011.95 | 1.91L (Cr) | |
| ₹1020.00 | ₹1034.15 | ₹1006.30 | ₹1025.20 | 2.31L (Cr) | |
| ₹1015.00 | ₹1027.15 | ₹1007.90 | ₹1025.65 | 1.73L (Cr) | |
| ₹1000.00 | ₹1023.50 | ₹989.05 | ₹1019.00 | 4.53L (Cr) | |
| ₹956.00 | ₹1021.55 | ₹953.30 | ₹997.75 | 13.67L (Cr) | |
| ₹928.00 | ₹954.20 | ₹918.00 | ₹950.30 | 3.17L (Cr) | |
| ₹919.00 | ₹930.00 | ₹901.20 | ₹924.50 | 4.98L (Cr) | |
| ₹905.00 | ₹910.80 | ₹891.20 | ₹907.90 | 1.26L (Cr) | |
| ₹907.60 | ₹911.70 | ₹893.60 | ₹900.30 | 63.91K (Cr) |
Jubilant Pharmova Limited — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹882.00 | ₹1041.00 | ₹873.60 | ₹1002.50 | +13.66% | |
| ₹936.00 | ₹995.00 | ₹847.85 | ₹881.90 | -5.78% | |
| ₹976.00 | ₹1042.00 | ₹931.00 | ₹935.15 | -4.19% | |
| ₹983.00 | ₹1004.70 | ₹939.05 | ₹970.90 | -1.23% | |
| ₹931.05 | ₹1031.70 | ₹927.25 | ₹995.00 | +6.87% | |
| ₹821.50 | ₹959.35 | ₹800.05 | ₹926.60 | +12.79% | |
| ₹828.60 | ₹886.30 | ₹786.05 | ₹816.45 | -1.47% | |
| ₹959.10 | ₹998.35 | ₹847.20 | ₹866.30 | -9.68% | |
| ₹1068.00 | ₹1107.80 | ₹926.90 | ₹981.90 | -8.06% | |
| ₹1089.70 | ₹1118.50 | ₹1011.00 | ₹1073.30 | -1.51% | |
| ₹1105.00 | ₹1183.00 | ₹1045.50 | ₹1089.70 | -1.38% | |
| ₹1078.90 | ₹1184.80 | ₹1033.00 | ₹1101.00 | +2.05% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Jubilant Pharmova Limited Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Jubilant Pharmova Limited Fundamental Analysis & Valuation Benchmarking
Educational evaluation of JUBLPHARMA across key market metrics for learning purposes.
Positive Indicators
3 factors identified
Strong Revenue Growth (17.29%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Healthy Liquidity Position (Current Ratio: 1.65)
Observation: Strong short-term liquidity to meet obligations.
Analysis: Current ratio >1.5 indicates good working capital management.
Strong Institutional Confidence (FII+DII: 27.53%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Risk Factors
7 factors identified
Below-Average Return on Equity (5.97%)
Observation: Returns on equity are below industry benchmarks.
Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.
Suboptimal ROCE (7.01%)
Observation: Returns on capital employed are below expectations.
Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.
Premium Valuation Risk (P/E: 45.10x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-45.09%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Weak Earnings Growth (-13.68% CAGR)
Observation: Below-average 5-year EPS growth performance.
Analysis: Low EPS growth may not keep pace with inflation.
Stagnant Profit Growth (-13.77% CAGR)
Observation: Limited 5-year profit growth trajectory.
Analysis: Low profit growth may indicate scalability challenges or market maturity.
Negative Free Cash Flow (₹-108.45 Cr over 5Y)
Observation: Cash outflows exceed inflows.
Analysis: Negative FCF requires analysis of capital expenditure cycle.
Jubilant Pharmova Limited vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Jubilant Pharmova Limited with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Jubilant Pharmova LimitedJubilant Pharmo...Selected✓ JUBLPHARMA • 530019 | 29.6/100 | ₹1002.50₹1003 | ₹15839.50₹15839.50 | 45.10Average 45.1 Average | 5.97%Poor 5.97% Poor | 7.01%Poor 7.01% Poor | 0.45Excellent 0.5 Excellent | -13.77%Poor -13.77% Poor | 6.31%Good 6.31% Good | 0.49% |
Sun Pharmaceutical Industries LimitedSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1876.50₹1877 | ₹450228.65₹450228.65 | 37.23Average 37.2 Average | 14.74%Average 14.74% Average | 19.31%Good 19.31% Good | 0.05Excellent 0.0 Excellent | 31.64%Excellent 31.64% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divi's Laboratories LimitedDivi's Laborato... DIVISLAB • 532488 | 56.3/100 | ₹9467.50₹9468 | ₹250888.75₹250888.75 | 85.90Average 85.9 Average | 16.19%Good 16.19% Good | 20.38%Excellent 20.38% Excellent | 0.00Excellent 0.0 Excellent | 5.29%Good 5.29% Good | 8.67%Good 8.67% Good | 0.41% |
Torrent Pharmaceuticals LimitedTorrent Pharmac... TORNTPHARM • 500420 | 51.4/100 | ₹4939.50₹4940 | ₹167182.32₹167182.32 | 78.91Average 78.9 Average | 27.07%Excellent 27.07% Excellent | 14.09%Average 14.09% Average | 1.76Average 1.8 Average | 11.56%Good 11.56% Good | 11.80%Good 11.80% Good | 0.76% |
Zydus Lifesciences LimitedZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1138.70₹1139 | ₹113642.26₹113642.26 | 25.38Average 25.4 Average | 19.74%Good 19.74% Good | 21.77%Excellent 21.77% Excellent | 0.43Excellent 0.4 Excellent | 18.76%Excellent 18.76% Excellent | 12.45%Good 12.45% Good | 0.09% |
Cipla LimitedCipla Limited... CIPLA • 500087 | 40.2/100 | ₹1371.90₹1372 | ₹110828.94₹110828.94 | 32.87Average 32.9 Average | 11.82%Average 11.82% Average | 15.67%Good 15.67% Good | 0.01Excellent 0.0 Excellent | 10.03%Good 10.03% Good | 8.01%Good 8.01% Good | 0.90% |
Laurus Labs LimitedLaurus Labs Lim... LAURUSLABS • 540222 | 34.1/100 | ₹1941.10₹1941 | ₹104867.93₹104867.93 | 95.81Average 95.8 Average | 18.19%Good 18.19% Good | 21.35%Excellent 21.35% Excellent | 0.45Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Aurobindo Pharma LimitedAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1683.00₹1683 | ₹96839.82₹96839.82 | 26.30Average 26.3 Average | 9.94%Poor 9.94% Poor | 14.54%Average 14.54% Average | 0.20Excellent 0.2 Excellent | -8.07%Poor -8.07% Poor | 6.32%Good 6.32% Good | 0.26% |
Lupin LimitedLupin Limited... LUPIN • 500257 | 83.4/100 | ₹2100.70₹2101 | ₹96054.51₹96054.51 | 17.36Average 17.4 Average | 26.90%Excellent 26.90% Excellent | 31.80%Excellent 31.80% Excellent | 0.26Excellent 0.3 Excellent | 34.39%Excellent 34.39% Excellent | 13.02%Good 13.02% Good | 0.72% |
Dr. Reddy's Laboratories LimitedDr. Reddy's Lab... DRREDDY • 500124 | 41/100 | ₹1144.50₹1145 | ₹95565.75₹95565.75 | 29.58Average 29.6 Average | 11.75%Average 11.75% Average | 14.80%Average 14.80% Average | 0.17Excellent 0.2 Excellent | 16.54%Excellent 16.54% Excellent | 12.09%Good 12.09% Good | 0.65% |
Mankind Pharma LimitedMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2293.70₹2294 | ₹94729.81₹94729.81 | 46.35Average 46.3 Average | 12.49%Average 12.49% Average | 13.56%Average 13.56% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Limited share price450228.65 Cr
- Divi's Laboratories Limited share price250888.75 Cr
- Torrent Pharmaceuticals Limited share price167182.32 Cr
- Zydus Lifesciences Limited share price113642.26 Cr
- Cipla Limited share price110828.94 Cr
Jubilant Pharmova Limited PE Ratio History
Historical price-to-earnings ratio for JUBLPHARMA — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹52.85 | ₹1073.30 | 20.3x |
| FY 2024 | ₹4.86 | ₹1105.20 | 227.4x |
| FY 2022 | ₹26.00 | ₹374.75 | 14.4x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Jubilant Pharmova Limited Dividend History
Annual cash dividends paid by JUBLPHARMA — dividend yield 0.49%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹79.60 Cr |
| FY 2024 | ₹79.80 Cr |
| FY 2023 | ₹80.10 Cr |
| FY 2022 | ₹80.05 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Jubilant Pharmova Limited Quarterly Performance
Latest quarterly metrics for JUBLPHARMA — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
17.29%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-45.09%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
6.31%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
-13.77%
Compounded annual net profit growth over 5 years
Jubilant Pharmova Limited Technical Indicators
SMA 50, SMA 200, RSI and volume signals for JUBLPHARMA — calculated from daily price history
Momentum is strong — price may be stretched. Watch for pullbacks.
Technical indicators are for educational purposes only. Not investment advice.
Jubilant Pharmova Limited Financial Statements
Annual income statement, balance sheet and cash flow for Jubilant Pharmova Limited (JUBLPHARMA) — sourced from NSE/BSE filings.
Financial Results & Statements
Latest quarterly, annual and period-wise financial data for Jubilant Pharmova Limited
About JUBLPHARMA (Jubilant Pharmova Limited)
Jubilant Pharmova Ltd is a global pharmaceutical powerhouse, deeply entrenched in the development, manufacturing, and distribution of a diverse portfolio of pharmaceutical products... and services. From its Indian roots, the company has expanded its footprint across the Americas, Europe, and beyond, becoming a key player in multiple therapeutic areas. Jubilant Pharmova's comprehensive business model spans the entire pharmaceutical value chain, encompassing research and development, active pharmaceutical ingredient (API) production, finished dosage formulation manufacturing, and contract manufacturing services. This vertically integrated approach allows for greater control over quality, cost, and supply chain efficiencies, positioning the company as a reliable partner for healthcare providers and pharmaceutical companies worldwide. The company’s operational structure is divided into strategic business segments, each focusing on specific areas of pharmaceutical expertise. These divisions range from the development and production of life-saving radiopharmaceuticals used in medical imaging and therapy, to allergy immunotherapy products designed to improve the lives of patients suffering from allergic conditions. Jubilant Pharmova also boasts a robust contract development and manufacturing organization (CDMO) specializing in sterile injectables, catering to the growing demand for specialized drug delivery systems. Furthermore, the company maintains a generics division focused on providing affordable medications, a contract research, development and manufacturing organization (CRDMO) division, and a proprietary novel drugs segment, highlighting its commitment to innovation and the development of new treatment modalities. Jubilant Pharmova’s unwavering commitment to quality, regulatory compliance, and innovation underpins its success in the global pharmaceutical landscape. The company invests heavily in research and development, constantly striving to improve existing products and develop novel therapies to address unmet medical needs. Its state-of-the-art manufacturing facilities adhere to the highest international standards, ensuring the safety and efficacy of its products. By fostering a culture of continuous improvement and a patient-centric approach, Jubilant Pharmova continues to solidify its position as a leading pharmaceutical company dedicated to improving global healthcare outcomes.
Company Details
Key Leadership
JUBLPHARMA Share Price: Frequently Asked Questions
What is the current share price of Jubilant Pharmova Limited?
Jubilant Pharmova Limited (JUBLPHARMA) trades at ₹1002.50 on NSE and BSE. Market cap ₹15.84K (Cr). Educational data only.
What is the P/E ratio of Jubilant Pharmova Limited?
Jubilant Pharmova Limited has a P/E of 45.10x vs industry average 34.89x.
What is the Bull Run score for Jubilant Pharmova Limited?
Jubilant Pharmova Limited has a Bull Run score of 29.6/100 based on 25+ financial parameters.
Does Jubilant Pharmova Limited pay dividends?
Jubilant Pharmova Limited has a dividend yield of 0.49%. Past dividends don't guarantee future payments.
What is the ROE of Jubilant Pharmova Limited?
Jubilant Pharmova Limited has ROE of 5.97%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Jubilant Pharmova Limited?
Jubilant Pharmova Limited has debt-to-equity of 0.45.
Is Jubilant Pharmova Limited a good investment?
Bull Run gives Jubilant Pharmova Limited a score of 29.6/100. This is not investment advice — consult a SEBI-registered advisor.